Clinical Trial Update: Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating inhaled carbon dioxide for apnea of prematurity in infants not responding to caffeine has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apnea of Prematurity

Drugs mentioned

• Inhaled carbon dioxide (carbon dioxide inhalation)

Snippet

Sponsor: University of Manitoba | Conditions: Apnea of Prematurity | Phase 2, Phase 3 | Status: TERMINATED